MedTrace Logo

Behavioral Drug and HIV Risk Reduction Counseling in Methadone Patients in China

NCT00757744 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 45

Last updated 2020-03-30

No results posted yet for this study

Summary

A randomized clinical trial evaluating the reduction of HIV risk behaviors and drug use when providing integrated behavioral drug and HIV risk reduction counseling (BDRC) along with methadone maintenance treatment in Wuhan, China

Conditions

  • Opiate Dependence
  • HIV Infections

Interventions

BEHAVIORAL

Behavioral Drug and HIV Risk Reduction Counseling (BDRC)

once weekly individual counseling

BEHAVIORAL

Drug counseling

individual drug counseling

Sponsors & Collaborators

  • National Institute on Drug Abuse (NIDA)

    collaborator NIH

  • Yale University

    lead OTHER

Principal Investigators

  • Richard S Schottenfeld, MD · Yale University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
FACTORIAL

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2010-01-31
Completion
2010-09-30

Countries

  • United States
  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00757744 on ClinicalTrials.gov